Department of Dermatology & Venereology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
J Eur Acad Dermatol Venereol. 2010 Mar;24(3):335-40. doi: 10.1111/j.1468-3083.2009.03417.x. Epub 2009 Sep 10.
Cutaneous leishmaniasis (CL) is a disease caused by leishmania species. Intralesional sodium stibogluconate (SSG) has been considered the first line therapy for localized cutaneous leishmaniasis. There is still a need for more effective and less time-consuming therapeutic methods for this condition.
The aim of the present study was to investigate if the combination of intramuscular (IM) SSG or oral ketoconazole with intralesional (IL) SSG would be more effective than the intralesional SSG given alone in the treatment of localized cutaneous leishmaniasis.
Thirty patients with confirmed diagnosis of cutaneous leishmaniasis were included in the study. They were randomly assigned to three groups. The first group (10 patients with 12 lesions) was treated with intralesional SSG alone. The second group (10 patients with 15 lesions) was treated with the combination of intralesional SSG + intramuscular SSG. The third group (10 patients with 13 lesions) was treated with the combination of intralesional SSG and oral ketoconazole. A follow-up was performed every 4 weeks for a treatment period of 12 weeks, then monthly for a period of 6 months after the end of the treatment.
Complete cure occurred in 58.3% of lesions in group 1, while 93.3% and 92.3% of lesions were cured in group 2 and 3 respectively. The difference between group 1 and the other groups was statistically significant (P < 0.05).
Combined intramuscular SSG or oral ketoconazole with intralesional SSG is more effective than intralesional SSG alone for the treatment of CL. Oral ketoconazole is much easier and safer therapy than intramuscular SSG in combination with intralesional SSG in the treatment of localized cutaneous leishmaniasis.
皮肤利什曼病(CL)是由利什曼原虫引起的疾病。病灶内注射葡萄糖酸锑钠(SSG)已被认为是治疗局限性皮肤利什曼病的一线疗法。对于这种疾病,仍然需要更有效和耗时更少的治疗方法。
本研究旨在探讨肌肉内(IM)SSG 或口服酮康唑与病灶内(IL)SSG 联合应用是否比单独病灶内 SSG 更有效治疗局限性皮肤利什曼病。
30 例确诊为皮肤利什曼病的患者纳入本研究。他们被随机分为三组。第一组(10 例患者 12 个病变)单独接受病灶内 SSG 治疗。第二组(10 例患者 15 个病变)接受病灶内 SSG+肌肉内 SSG 联合治疗。第三组(10 例患者 13 个病变)接受病灶内 SSG 和口服酮康唑联合治疗。治疗期间每 4 周进行一次随访,共 12 周,治疗结束后每月随访一次,持续 6 个月。
第 1 组 58.3%的病变完全治愈,第 2 组和第 3 组分别有 93.3%和 92.3%的病变治愈。第 1 组与其他组之间的差异具有统计学意义(P<0.05)。
病灶内注射 SSG 联合肌肉内 SSG 或口服酮康唑比单独病灶内注射 SSG 更有效治疗 CL。与病灶内注射 SSG 联合肌肉内 SSG 相比,口服酮康唑在治疗局限性皮肤利什曼病时更为简便、安全。